Iferanserin
Phase 3Small molecule
Iferanserin is one of 27 small molecule programs targeting Hemorrhoid. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Cardizem
BBausch Health Americas, Inc.
Approved
Marcaine
IInnocoll
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Flagyl
DDePuy Orthopaedics
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
SKY0402
Pacira Pharmaceuticals, IncPhase 3
Botox
RRevance Therapeutics, Inc.
Phase 2
Centella
UUniversity of Roma La Sapienza
Approved
Xylocaine
CCitius Pharmaceuticals, Inc.
Phase 2
Morphine Chloride
FFundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iferanserin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVentrus Biosciences, Inc